Metastatic Melanoma Pipeline H2 2015 Report on Drugs and Companies

Jan 29, 2016, 07:30 ET from ReportsnReports

PUNE, India, January 29, 2016 /PRNewswire/ -- adds "Metastatic Melanoma - Pipeline Review, H2 2015" market research report that provides an overview of the Metastatic Melanoma's therapeutic pipeline with comprehensive information and comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Complete report on H2 2015 pipeline review of Metastatic Melanoma with 109 market data tables and 17 figures, spread across 623 pages is available at .

Companies discussed in this Metastatic Melanoma - Pipeline Review, H2 2015 report include AB Science SA, AbbVie Inc., Adaptimmune Limited, Affichem SA, Agalimmune Ltd, Agenus, Inc., AGV Discovery, SAS, Altor BioScience Corporation, Amgen Inc., Arisaph Pharmaceuticals, Inc., Array BioPharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, Basilea Pharmaceutica AG, Bioncotech Therapeutics S.L., Bionomics Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Caladrius Biosciences, Inc., cCAM Biotherapeutics Ltd., Cellceutix Corporation, Celldex Therapeutics, Inc., Delcath Systems, Inc., Digna Biotech, S.L., DNA Therapeutics S.A., Dynavax Technologies Corporation, Eisai Co., Ltd., Eli Lilly and Company, Ensol Biosciences Inc., F. Hoffmann-La Roche Ltd., Galapagos NV, Galectin Therapeutics, Inc., GlaxoSmithKline Plc, Idera Pharmaceuticals, Inc., Immune Design Corp., ImmuRx, Inc., Incyte Corporation, IO Biotech ApS, Life Science Pharmaceuticals, Incorporated, Lipotek Pty Ltd., Luitpold Pharmaceuticals, Inc., MacroGenics, Inc., MedImmune, LLC, Medivation, Inc., MELEMA Pharma GmbH, Memgen, LLC., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals, Inc., Morphotek, Inc., NewLink Genetics Corporation, Novartis AG, Omeros Corporation, Oncolytics Biotech Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Pharmis Biofarmaceutica, Lda., Philogen S.p.A., Plexxikon Inc., Polaris Pharmaceuticals, Inc., Polyphor Ltd., Prima BioMed Ltd., Provectus Biopharmaceuticals, Inc., Provenance Biopharmaceuticals Corp., Reata Pharmaceuticals, Inc., RXi Pharmaceuticals Corporation, Scancell Holdings Plc, Syndax Pharmaceuticals, Inc., Takara Bio Inc., TC BioPharm Limited, Tikcro Technologies, Ltd. and Ultimovacs AS.

Order a copy of this report @ .

Drug Profiles mentioned in this report are (dabrafenib mesylate + trametinib dimethyl sulfoxide), A-dmDT390-bisFv, abemaciclib, AF-122, AGI-134, ALT-801, ALT-803, AMG-232, Anti-CSPG4-IL2, Antibody to Inhibit SP90 for Metastatic Melanoma, ARI-4175, atezolizumab, austrasulfone, aviscumine, BAL-3833, bevacizumab, binimetinib + encorafenib, BL-011256, BNC-420, BO-110, buparlisib hydrochloride, cancer vaccine, capmatinib, CB-745, Cellular Immunotherapy 1 for Metastatic Melanoma, Cellular Immunotherapy 2 for Metastatic Melanoma, Cellular Immunotherapy 2 for Metastatic Melanoma, Cellular Immunotherapy for Cancer and Viral Infections, Cellular Immunotherapy for Metastatic Melanoma, Cellular Immunotherapy for Metastatic Melanoma, Cellular Immunotherapy to Target HERV-K for Metastatic Melanoma, Cellular Immunotherapy to Target MAGE-A6, MART-1 and Tyrosinase for Metastatic Melanoma, Cellular Immunotherapy to Target MART-1 and MELOE-1 for Metastatic Melanoma, Cellular Immunotherapy to Target MART-1 for Metastatic Melanoma, Cellular Immunotherapy to Target NY-ESO-1 for Metastatic Melanoma, Cellular Immunotherapy to Target NY-ESO-1 for Oncology, Charis-1000, CM-24, dabrafenib mesylate,dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide, Darleukin, DB-039, diphencyprone, DNA IL-12, Drugs to Antagonize ETBR for Metastatic elanoma, DT-01, E-6201, ecromeximab, eltrapuldencel-T, encorafenib, enoblituzumab, entinostat, epacadostat, FC-311, G-305, glembatumumab vedotin, GLPG-1790, GRMD-02, GSK-2241658A, GSK-2302025A, GSK-3377794, guadecitabine, HF-10, ICOVIR-5, IMO-2125, IMP-321, indoximod, IO-102, ISF-35, KM-3174, lenvatinib, lirilumab, LN-144, LOC-paclitaxel, LV-305, LY-3009120, M-200, masitinib, MEDI-3617, melphalan, miRNA-7-5p, MK-0429, Monoclonal Antibodies to Antagonise PD1 for Metastatic Melanoma and Metastatic Lung Cancer, Monoclonal Antibodies to Inhibit CTLA-4 for Metastatic Melanoma, Monoclonal Antibody to Inhibit CD40 for Metastatic Melanoma, MORAb-050, navitoclax dihydrochloride, nilotinib, nintedanib, nivolumab, omaveloxolone, onalespib, ontuxizumab, palbociclib, panobinostat, pasireotide, PDC-mel, pegargiminase, pelareorep, pembrolizumab, pexidartinib, pidilizumab, pimasertib hydrochloride, POL-7085, PV-10, Q-122, Q-204, RAF-265, Recombinant Protein for Metastatic Melanoma, Recombinant Protein for Oncology, ribociclib, SCIB-1, SD-101, Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer, Small Molecules to Antagonize ET-B for Oncology, Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma, Small Molecules to Inhibit P-Selectin, L-Selectin and PMN Proteases for Cancer, SRX-1177, sunitinib malate, TAK-580, talimogene laherparepvec, TMECG, TPI-287, trametinib dimethyl sulfoxide, tremelimumab + MEDI-3617, UV-1, Vaccine for Metastatic Melanoma, varlilumab, veliparib, vemurafenib, ZSG-101 and ZSG-102.

Explore more reports on Pharmaceuticals industry at .

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441

Connect With Us on:  



Twitter: https: //

G+ / Google Plus:

RSS/Feeds:  http: //

SOURCE ReportsnReports